SCHEMBL5451343

SCHEMBL5451343

CON(C)C(=O)c1cn(CCCCl)c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 9/20 0.52
CNR1 P21554 6/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 2/20 0.52
KMT2A Q03164 1/20 0.52
TSHR P16473 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PTPN7 P35236 1/20 0.51
DUSP3 P51452 1/20 0.51
LMNA P02545 3/20 0.49
MAPT P10636 3/20 0.49
NR4A2 P43354 1/20 0.49
NPSR1 Q6W5P4 2/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451251 0.81 CNR2 (0.50) CNR2CNR1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL5456434 0.81 CNR2 (0.51) CNR2CNR1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL5332746 0.80 SMN1; SMN2 (0.71) CNR2CNR1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL5454223 0.80 CNR2 (0.48) CNR2CNR1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL14412214 0.80 DRD3 (0.50) CNR2CNR1SMN1; SMN2ALDH1A1
SCHEMBL5445041 0.80 CNR2 (0.48) CNR2CNR1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL5454811 0.79 CNR2 (0.52) CNR2CNR1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL13694124 0.79 NR4A2 (0.63) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
Hydrochloric Acid SCHEMBL5454205 0.79 ADRA1D (0.55) CNR2LMNA
SCHEMBL5318855 0.79 CNR2 (0.47) CNR2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
WO-2007079239-A2 BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF GIPR, GHSR, GHRHR CNR2 106/4885CNR1 65/4885SMN1; SMN2 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.